The Efficacy of Coenzyme Q10 in Combination With Atorvastatin on Coronary Heart Disease

Abstract

The aim of this study was to evaluate the efficacy of coenzyme Q10 (CoQ10) in combination with atorvastatin on coronary heart disease (CHD). In this study there were included 84 patients with CHD and divided into two groups, a control group (42 patients), treated with atorvastatin and an experimental group (42 patients) that received atorvastatin and CoQ10. CoQ10 levels, transaminase activities (ALT and AST), blood lipid, cardiac function, and hemodynamic, were measured and evaluated before the treatment and 3 months after the treatment. Both treatments were safe and effective in the clinical management if lipidic imbalance in CHD, but the experimental group had better therapeutic effects. The CoQ10 level in the experimental group increased after the treatment (p < 0.05), while in the control group decreased significantly (p < 0.05). ALT and AST levels did not changed significantly after the treatment in the experimental group, while in the control group, it was observed a significant increase (p < 0.05). After treatment, the left ventricular diastolic function of the experimental group was improved significantly (p < 0.05). Meanwhile, the left ventricular diastolic function of the control group was also improved to some extent, but the difference was not statistically significant (p > 0.05). In conclusion, CoQ10 supplementation could avoid the increase of transaminases caused by atorvastatin, and could enhance the lipid-lowering effect of atorvastatin and improve the cardiac function effectively. RezumatScopul acestui studiu a fost evaluarea eficacității coenzimei Q10 (CoQ10) în combinație cu atorvastatina în bolile coronariene (CHD). Au fost incluși 84 de pacienți cu CHD, împărțiți în două grupuri, control (42 de pacienți), grupul tratat cu atorvastatină și un grup experimental (42 de pacienți) care a primit atorvastatină și CoQ10. Nivelurile CoQ10, activitatea transaminazelor (ALT și AST), a lipidelor plasmatice, funcția cardiacă și hemodinamica au fost evaluate înainte de tratament și după 3 luni. Ambele terapii au fost sigure și eficiente în managementul clinic al dezechilibrului lipidic în CHD, dar grupul experimental a prezentat efecte terapeutice superioare. Nivelul CoQ10 în grupul experimental a crescut după tratament (p < 0,05), în timp ce în grupul martor a scăzut semnificativ (p < 0,05). Nivelurile ALT și AST nu s-au modificat semnificativ după tratament în grupul experimental, în timp ce în grupul martor s-a observat o creștere semnificativă (p < 0,05). După tratament, funcția diastolică a ventriculului stâng în grupul experimental a fost îmbunătățită. Funcția diastolică a ventriculului stâng în grupul martor a fost, de asemenea, îmbunătățită. În concluzie, suplimentarea cu CoQ10 ar putea evita creșterea transaminazelor în terapia cu atorvastatină, și ar putea îmbunătăți profilul lipidic și funcția cardiacă.

The effect of coenzyme Q10 supplementation on liver enzymes: A systematic review and meta‐analysis of randomized clinical trials

“…Moreover, two eligible articles were published on the same dataset (Farhangi et al, 2014; Jafarvand et al, 2016), of which the more complete one was included (Farhangi et al, 2014), and the other one was excluded (Jafarvand et al, 2016). After these exclusions, 15 eligible RCTs remained for inclusion in the current systematic review and meta‐analysis (Derosa et al, 2019; Diaz‐Castro et al, 2020; Emami & Bazargani‐Gilani, 2018; Farhangi et al, 2014; Farsi et al, 2016; Gholami et al, 2019; Hernández‐Ojeda et al, 2012; Kuhlman et al, 2019; Mabuchi et al, 2007; Nevzat, 2015; Pek et al, 2016; Rodríguez‐Carrizalez et al, 2016; Serag et al, 2020; Wang et al, 2020; Yasser et al, 2021); Of these, 13 studies assessed serum concentrations of ALT and AST (Derosa et al, 2019; Emami & Bazargani‐Gilani, 2018; Farhangi et al, 2014; Farsi et al, 2016; Kuhlman et al, 2019; Mabuchi et al, 2007; Nevzat, 2015; Pek et al, 2016; Rodríguez‐Carrizalez et al, 2016; Serag et al, 2020; Wang et al, 2020; Yasser et al, 2021), six studies examined serum concentrations of GGT (Emami & Bazargani‐Gilani, 2018; Farsi et al, 2016; Gholami et al, 2019; Hernández‐Ojeda et al, 2012; Nevzat, 2015; Pek et al, 2016), and four studies evaluated serum concentration of ALP following coenzyme Q10 supplementation (Diaz‐Castro et al, 2020; Hernández‐Ojeda et al, 2012; Nevzat, 2015; Pek et al, 2016). The study conducted by Nevzat et al (2015) compared the effects of two doses of coenzyme Q10 supplementation (100 and 200 mg/day) with placed in their study, and also for Emami and Bazargani‐Gilani (2018) study that divided participants into four groups (supplement only, supplement with precooling strategy, and control groups), we extracted two effect sizes from these studies and included them in our meta‐analysis as two separate studies.…”

“…The characteristics of 15 RCTs in the current systematic review and meta‐analysis are illustrated in Table 1 . These RCTs were published between 2007 and 2021 and were from Asia (Emami & Bazargani‐Gilani, 2018 ; Farhangi et al, 2014 ; Farsi et al, 2016 ; Gholami et al, 2019 ; Mabuchi et al, 2007 ; Nevzat, 2015 ; Pek et al, 2016 ; Wang et al, 2020 ; Yasser et al, 2021 ), Europe (Derosa et al, 2019 ; Diaz‐Castro et al, 2020 ; Kuhlman et al, 2019 ), Mexico (Hernández‐Ojeda et al, 2012 ; Rodríguez‐Carrizalez et al, 2016 ), and Egypt (Serag et al, 2020 ). Three studies were exclusively performed on male subjects (Diaz‐Castro et al, 2020 ; Emami & Bazargani‐Gilani, 2018 ; Nevzat, 2015 ), one study on females (Gholami et al, 2019 ), and others on both genders.…”

“…Moreover, two eligible articles were published on the same dataset (Farhangi et al, 2014;Jafarvand et al, 2016), of which the more complete one was included (Farhangi et al, 2014), and the other one was excluded (Jafarvand et al, 2016). After these exclusions, 15 eligible RCTs remained for inclusion in the current systematic review and meta-analysis (Derosa et al, 2019;Diaz-Castro et al, 2020;Emami & Bazargani-Gilani, 2018;Farhangi et al, 2014;Farsi et al, 2016;Gholami et al, 2019;Hernández-Ojeda et al, 2012;Kuhlman et al, 2019;Mabuchi et al, 2007;Nevzat, 2015;Pek et al, 2016;Rodríguez-Carrizalez et al, 2016;Serag et al, 2020;Wang et al, 2020;Yasser et al, 2021); Of these, 13 studies assessed serum concentrations of ALT and AST (Derosa et al, 2019;Emami Bazargani-Gilani (2018) study that divided participants into four groups (supplement only, supplement with precooling strategy, and control groups), we extracted two effect sizes from these studies and included them in our meta-analysis as two separate studies. The flow diagram of study selection is outlined in Figure 1.…”

“…&Bazargani-Gilani, 2018;Farhangi et al, 2014;Farsi et al, 2016;Kuhlman et al, 2019;Mabuchi et al, 2007;Nevzat, 2015;Pek et al, 2016;Rodríguez-Carrizalez et al, 2016;Serag et al, 2020;Wang et al, 2020;Yasser et al, 2021), six studies examined serum concentrations of GGT(Emami & Bazargani-Gilani, 2018;Farsi et al, 2016;Gholami et al, 2019;Hernández-Ojeda et al, 2012;Nevzat, 2015;Pek et al, 2016), and four studies evaluated serum concentration of ALP following coenzyme Q10 supplementation(Diaz- Castro et al, 2020;Hernández-Ojeda et al, 2012;Nevzat, 2015;Pek et al, 2016). The study conducted byNevzat et al (2015) compared the effects of two doses of coenzyme Q10 supplementation (100 and 200 mg/day) with placed in their study, and also for Emami and | 4915 SOLEIMANI DAMANEH et al…”

Statins and the Risk for Coronary in-Stent Restenosis in Diabetic Patients

“…Moreover, data provided by the Lescol Intervention Prevention Study (LIPS) sub-study show that statins reduce the impact of diabetes on long-term outcome after coronary intervention and also decrease the risk of major adverse cardiovascular events in diabetic patients by over 50% [33]. The efficacity of statins is mainly due to their pleiotropic effects rather than their lipid-lowering success [34,40,41]. In addition to lowering cholesterol, they have many other effects (anti-inflammatory, antithrombotic, antioxidant, lowering the level of C-reactive protein, antimitoticinhibiting the proliferation of smooth muscle cells, increasing the synthesis of nitric oxide and stimulating the expression and activity of endothelial nitric oxide synthase) [10].…”